
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is a promising biopharmaceutical company with a strong clinical pipeline focused on next-generation programmed T-cell therapies for the treatment of cancer, specifically in r/r ALL. Their current clinical trials, potential expansion into earlier lines of therapy, and positive feedback from experts in the field make Autolus a compelling investment opportunity with potential for revenue growth and market expansion.
Bears say
Autolus Therapeutics is facing significant challenges with its pipeline, including the need for earlier data from its clinical trials and concerns about potential commercial viability. While the company's T cell programming technologies show potential, the lack of options for SOC refractory LN patients and the potential for lower than expected payor reimbursement put the success of its LUMINA trial and overall market potential at risk. Additionally, the company's focus on fast-to-market strategies may not be enough to overcome the limited production capabilities for its CAR-T therapies, further limiting its potential in the market.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares